Company news
Mbx Biosciences, Inc. (NASDAQ:MBX) news
Every Mbx Biosciences, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
September 8, 2026
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyro...
August 27, 2026
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
August 6, 2026
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
July 13, 2026
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Thera...
June 12, 2026
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
June 1, 2026
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
May 26, 2026
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
May 11, 2026
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
May 7, 2026
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
April 23, 2026
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 3, 2026
Microbix Announces Annual Meeting Voting Results
March 26, 2026
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
March 12, 2026
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
March 10, 2026
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for H...
March 9, 2026
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-...
March 9, 2026
MBX Biosciences to Participate in Upcoming March Investor Conferences
February 23, 2026
MBX Biosciences to Participate in Upcoming Investor Conferences
February 11, 2026
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
January 22, 2026
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
January 11, 2026
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
December 15, 2025
MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference
November 18, 2025
MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 6, 2025
MBX Biosciences to Participate in November Investor Conferences
October 20, 2025
MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum
September 29, 2025
MBX Biosciences Announces Pricing of Upsized Public Offering
September 24, 2025
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% R...
September 22, 2025
MBX Biosciences Announces Proposed Public Offering
September 22, 2025
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on M...
September 19, 2025
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
September 4, 2025
MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
August 7, 2025
MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development
June 23, 2025
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity
June 16, 2025
MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions
June 10, 2025
MBX Biosciences to Participate in June Investor Conferences
May 20, 2025
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
May 12, 2025
MBX Biosciences to Participate in Citizens and RBC May Investor Conferences
April 22, 2025
MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors
April 7, 2025
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 26, 2025
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
March 17, 2025
MBX Biosciences Announces Additions to Leadership Team
March 5, 2025
MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism
March 3, 2025
MBX Biosciences to Participate in March Investor Conferences
February 18, 2025
MBX Biosciences to Participate in Upcoming February Investor Conferences
January 23, 2025
MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia
January 7, 2025
MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference
December 18, 2024
MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism
December 2, 2024
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
November 18, 2024
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 7, 2024
MBX Biosciences to Participate in Upcoming November Investor Conferences
October 28, 2024